{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:28:51Z","timestamp":1788312531607,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"China Postdoctoral Science Foundation funded project","award":["2024M762019"],"award-info":[{"award-number":["2024M762019"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500203"],"award-info":[{"award-number":["82500203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300653"],"award-info":[{"award-number":["32300653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(82170145,82100422,82322067,82470152,82400092"],"award-info":[{"award-number":["(82170145,82100422,82322067,82470152,82400092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(82170145,82100422,82322067,82470152,82400092"],"award-info":[{"award-number":["(82170145,82100422,82322067,82470152,82400092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(82170145,82100422,82322067,82470152,82400092"],"award-info":[{"award-number":["(82170145,82100422,82322067,82470152,82400092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(82170145,82100422,82322067,82470152,82400092"],"award-info":[{"award-number":["(82170145,82100422,82322067,82470152,82400092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai sailing program","award":["21YF1423100"],"award-info":[{"award-number":["21YF1423100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) remains a challenging hematologic malignancy with limited treatment options and poor prognosis. Here, we report the development of a multifunctional, pH-responsive, and biodegradable nanoparticle system, Membrane\/Cu-HMPB@DSF\/RSL3, for synergistic AML therapy. Constructed upon the Prussian blue-based frameworks and cloaked with leukemia cell membranes, these nanoparticles preferentially accumulate in AML cells and release copper, iron, and manganese ions, along with disulfiram (DSF) and RSL3, under mildly acidic intracellular conditions. The released metal ions catalyze Fenton-like reactions, deplete intracellular glutathione (GSH), and induce ferroptosis and cuproptosis in cooperation with the loaded small-molecule drugs. Meanwhile, manganese ions activate the cGAS-STING pathway, triggering innate immune responses and promoting immune cell recruitment. Both in vitro and in vivo studies demonstrated robust anti-AML efficacy with minimal systemic toxicity. This work presents a modular and immunogenic nanoplatform that holds broad potential for AML treatment and beyond.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-026-04295-4","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:16:52Z","timestamp":1774084612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A degradable multi-metal-chelating stealth nanoplatform for dual ferroptosis\/cuproptosis-enhanced metalloimmunotherapy in leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Yingying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"4295_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet (London England). 2023;401:2073\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(23)00108-3.","journal-title":"Lancet (London England)"},{"key":"4295_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"4295_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry MZ, et al. A review of treatment options employed in relapsed\/refractory AML. Hematology (Amsterdam, Netherlands). 2023;28:2196482. https:\/\/doi.org\/10.1080\/16078454.2023.2196482.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"4295_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/moh.0000000000000686","volume":"28","author":"AE Austin","year":"2021","unstructured":"Austin AE, Byrne M. Detecting and preventing post-hematopoietic cell transplant relapse in AML. Curr Opin Hematol. 2021;28:380\u20138. https:\/\/doi.org\/10.1097\/moh.0000000000000686.","journal-title":"Curr Opin Hematol"},{"key":"4295_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66. https:\/\/doi.org\/10.1007\/s11864-020-00765-5.","journal-title":"Curr Treat Options Oncol"},{"key":"4295_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"4295_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11:104. https:\/\/doi.org\/10.1038\/s41408-021-00495-3.","journal-title":"Blood Cancer J"},{"key":"4295_CR8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/jco.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2024;42:1499\u2013508. https:\/\/doi.org\/10.1200\/jco.23.01911.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4295_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How i treat patients with AML using azacitidine and venetoclax. Blood. 2025;145:1237\u201350. https:\/\/doi.org\/10.1182\/blood.2024024009.","journal-title":"Blood"},{"key":"4295_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer drug Resist (Alhambra Calif). 2022;5:380\u2013400. https:\/\/doi.org\/10.20517\/cdr.2021.125.","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"key":"4295_CR11","doi-asserted-by":"publisher","first-page":"279.e271","DOI":"10.1016\/j.jtct.2022.12.013","volume":"29","author":"MC Tokaz","year":"2023","unstructured":"Tokaz MC, et al. An analysis of the worldwide utilization of hematopoietic stem cell transplantation for acute myeloid leukemia. Transplant Cell Ther. 2023;29:279.e271-279.e210. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.013.","journal-title":"Transplant Cell Ther"},{"key":"4295_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","volume":"20","author":"M de Lima","year":"2014","unstructured":"de Lima M, et al. Proceedings from the National Cancer Institute\u2019s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20:4\u201313. https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.012.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4295_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41375-023-02117-2","volume":"38","author":"H Akiyama","year":"2024","unstructured":"Akiyama H, et al. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024;38:729\u201340. https:\/\/doi.org\/10.1038\/s41375-023-02117-2.","journal-title":"Leukemia"},{"key":"4295_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2024.127517","volume":"86","author":"M Wu","year":"2024","unstructured":"Wu M, et al. The novel prognostic analysis of AML based on ferroptosis and cuproptosis related genes. J Trace Elem Med Biol. 2024;86:127517. https:\/\/doi.org\/10.1016\/j.jtemb.2024.127517.","journal-title":"J Trace Elem Med Biol"},{"key":"4295_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.176","volume":"8","author":"B Xu","year":"2017","unstructured":"Xu B, et al. Disulfiram\/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-\u03baB and Nrf2. Cell Death Dis. 2017;8:e2797. https:\/\/doi.org\/10.1038\/cddis.2017.176.","journal-title":"Cell Death Dis"},{"key":"4295_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1549294","volume":"12","author":"Z Chai","year":"2024","unstructured":"Chai Z, Yuan Z, Chen Y. Stem cell status and prognostic applications of cuproptosis-associated lncRNAs in acute myeloid leukemia. Front Cell Dev Biol. 2024;12:1549294. https:\/\/doi.org\/10.3389\/fcell.2024.1549294.","journal-title":"Front Cell Dev Biol"},{"key":"4295_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1397-3","volume":"38","author":"F Wang","year":"2019","unstructured":"Wang F, et al. Iron and leukemia: new insights for future treatments. J Exp Clin Cancer Res. 2019;38:406. https:\/\/doi.org\/10.1186\/s13046-019-1397-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"4295_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2019.02.011","volume":"80","author":"M Gasparetto","year":"2019","unstructured":"Gasparetto M, et al. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019;80:1\u201310. https:\/\/doi.org\/10.1016\/j.leukres.2019.02.011.","journal-title":"Leuk Res"},{"key":"4295_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01822-7","volume":"29","author":"MH Ashoub","year":"2024","unstructured":"Ashoub MH, Razavi R, Heydaryan K, Salavati-Niasari M, Amiri M. Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology. Eur J Med Res. 2024;29:224. https:\/\/doi.org\/10.1186\/s40001-024-01822-7.","journal-title":"Eur J Med Res"},{"key":"4295_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10486-7","volume":"23","author":"T Li","year":"2023","unstructured":"Li T, Shi L, Wei W, Xu J, Liu Q. The trace that is valuable: serum copper and copper to zinc ratio for survival prediction in younger patients with newly diagnosed acute myeloid leukaemia. BMC Cancer. 2023;23:14. https:\/\/doi.org\/10.1186\/s12885-022-10486-7.","journal-title":"BMC Cancer"},{"key":"4295_CR21","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s12094-023-03118-4","volume":"25","author":"D Luo","year":"2023","unstructured":"Luo D, et al. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia. Clin Transl Oncol. 2023;25:2393\u2013407. https:\/\/doi.org\/10.1007\/s12094-023-03118-4.","journal-title":"Clin Transl Oncol"},{"key":"4295_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101018","volume":"72","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat. 2024;72:101018. https:\/\/doi.org\/10.1016\/j.drup.2023.101018.","journal-title":"Drug Resist Updat"},{"key":"4295_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao M, et al. Role of mitochondria in ferroptosis. Mol Cell. 2019;73:354-363.e353. https:\/\/doi.org\/10.1016\/j.molcel.2018.10.042.","journal-title":"Mol Cell"},{"key":"4295_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061505","author":"AM Battaglia","year":"2020","unstructured":"Battaglia AM, et al. Ferroptosis and cancer: mitochondria meet the \u201cIron Maiden\u201d cell death. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9061505.","journal-title":"Cells"},{"key":"4295_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01267-1","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death. Cell Commun Signal. 2023;21:327. https:\/\/doi.org\/10.1186\/s12964-023-01267-1.","journal-title":"Cell Commun Signal"},{"key":"4295_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116115","volume":"171","author":"N Liu","year":"2024","unstructured":"Liu N, Chen M. Crosstalk between ferroptosis and cuproptosis: from mechanism to potential clinical application. Biomed Pharmacother. 2024;171:116115. https:\/\/doi.org\/10.1016\/j.biopha.2023.116115.","journal-title":"Biomed Pharmacother"},{"key":"4295_CR27","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3:1452\u201363. https:\/\/doi.org\/10.1038\/s43018-022-00468-w.","journal-title":"Nat Cancer"},{"key":"4295_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81. https:\/\/doi.org\/10.1186\/s13045-020-00916-z.","journal-title":"J Hematol Oncol"},{"key":"4295_CR29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30:966\u201379. https:\/\/doi.org\/10.1038\/s41422-020-00395-4.","journal-title":"Cell Res"},{"key":"4295_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310189","volume":"36","author":"H Yang","year":"2024","unstructured":"Yang H, Yang S, Guo Q, Sheng J, Mao Z. ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy. Adv Mater. 2024;36:e2310189. https:\/\/doi.org\/10.1002\/adma.202310189.","journal-title":"Adv Mater"},{"key":"4295_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biomaterials.2015.01.012","volume":"48","author":"J Li","year":"2015","unstructured":"Li J, Liu W, Wu X, Gao X. Mechanism of pH-switchable peroxidase and catalase-like activities of gold, silver, platinum and palladium. Biomaterials. 2015;48:37\u201344. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.01.012.","journal-title":"Biomaterials"},{"key":"4295_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2019.124942","volume":"240","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Comparison of toxicity induced by EDTA-Cu after UV\/H(2)O(2) and UV\/persulfate treatment: species-specific and technology-dependent toxicity. Chemosphere. 2020;240:124942. https:\/\/doi.org\/10.1016\/j.chemosphere.2019.124942.","journal-title":"Chemosphere"},{"key":"4295_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.molonc.2015.02.007","volume":"9","author":"JL Allensworth","year":"2015","unstructured":"Allensworth JL, et al. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol. 2015;9:1155\u201368. https:\/\/doi.org\/10.1016\/j.molonc.2015.02.007.","journal-title":"Mol Oncol"},{"key":"4295_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.scib.2023.02.027","volume":"68","author":"JL Liang","year":"2023","unstructured":"Liang JL, et al. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Sci Bull. 2023;68:622\u201336. https:\/\/doi.org\/10.1016\/j.scib.2023.02.027.","journal-title":"Sci Bull"},{"key":"4295_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121836","author":"JC Harris","year":"2019","unstructured":"Harris JC, Scully MA, Day ES. Cancer cell membrane-coated nanoparticles for cancer management. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11121836.","journal-title":"Cancers"},{"key":"4295_CR36","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/nl500618u","volume":"14","author":"RH Fang","year":"2014","unstructured":"Fang RH, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181\u20138. https:\/\/doi.org\/10.1021\/nl500618u.","journal-title":"Nano Lett"},{"key":"4295_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20:33\u201348. https:\/\/doi.org\/10.1038\/s41571-022-00699-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"4295_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2024.11.002","author":"VC Deivayanai","year":"2024","unstructured":"Deivayanai VC, et al. A comprehensive review on advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives. Cancer Pathogenesis Therapy. 2024. https:\/\/doi.org\/10.1016\/j.cpt.2024.11.002.","journal-title":"Cancer Pathogenesis Therapy"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04295-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:17:18Z","timestamp":1777432638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04295-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4295"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04295-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}